THE Rolf M. Schwiete Foundation (Mannheim, Germany) you have selected a research from the Cima University of Navarre which improves the early diagnosis of biliary tumors. Scientists will validate effectiveness of bile study developed by the Cima Hepatology Group.
THE biliary tumors such as cholangiocarcinoma are usually diagnosed in advanced stages which conditions a bad prognosiswith a five-year survival rate of less than 20%. Therefore, Early detection is essential to improve prognosis of these patients.
A collaborative study coordinated by Cima has recently developed a new strategy to diagnose these types of tumors with great efficiency. “This strategy, called Bilemut, is based on the analysis of DNA present in bile by massive sequencing to detect mutations. Previous studies have confirmed that this procedure determines the presence of a tumor with a much higher degree of precision than current diagnostic methods,” explain Drs. Matías Ávila and Carmen Berasain, principal investigators of the Cima Hepatology Laboratory and members of the CIBER in Liver and Digestive Diseases (CIBERehd).
” Thanks to grant from the Rolf M. Schwiete Foundation, endowed with 250,000 euros“We will be able to validate in new cohorts of patients the effectiveness of this diagnostic method, immediately applicable in clinical practice. To do this, we will collaborate with Dr. Marcin Krawczyk, from the University of Essen in Germany,” explain the researchers of the group María Arechederra and Maite García.
The Bilemut application could modify the current diagnostic scenario by allowing detect the presence of a tumor early and with high sensitivitywhich allows to select personalized care. In addition, its application would avoid the repetition of diagnostic procedures, thus reducing the risk of complications and medical costs.
